Targeting the Ubiquitin System for Drug Discovery

Venue: Park Hyatt at the Bellevue

Location: Philadelphia, Pennsylvania, United States

Event Date/Time: Jun 21, 2004 End Date/Time: Jun 22, 2004
Registration Date: May 21, 2004
Early Registration Date: Apr 30, 2004
Report as Spam


With the recent clinical validation of VELCADE, the first proteasome inhibitor to be approved by the FDA for cancer therapy, interest has exploded in the ubiquitin-proteasome pathway field. In addition to cancer, research in under way for the potential of therapeutic intervention in many other disease areas such as antiviral, osteoporosis and muscular atrophy.